MammaPrint® has the Answer.
The majority of women with early-stage breast cancer have a Low Risk of cancer relapse and may safely avoid chemotherapy.1 So how do you know if chemotherapy will benefit you? The MammaPrint® 70-Gene Assay is the only FDA-cleared risk of recurrence test that provides a personalized, definitive result so you can know with certainty if you are at Low Risk for cancer relapse – and not likely to benefit from chemotherapy.
1. Cardoso F, van’t Veer LJ, Bogaerts J et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; 375:717-29.
LOCATE A PHYSICIAN >>